Abstract

Ischemia reperfusion injury (IRI) is one of the most important mechanisms involved in delayed or reduced graft function after kidney transplantation. It is a complex pathophysiological process, followed by a pro-inflammatory response that enhances the immunogenicity of the graft and the risk of acute rejection. Many biologic processes are involved in its development, such as transcriptional reprogramming, the activation of apoptosis and cell death, endothelial dysfunction and the activation of the innate and adaptive immune response. Recent evidence has highlighted the importance of complement activation in IRI cascade, which expresses a pleiotropic action on tubular cells, on vascular cells (pericytes and endothelial cells) and on immune system cells. The effects of IRI in the long term lead to interstitial fibrosis and tubular atrophy, which contribute to chronic graft dysfunction and subsequently graft failure. Furthermore, several metabolic alterations occur upon IRI. Metabolomic analyses of IRI detected a “metabolic profile” of this process, in order to identify novel biomarkers that may potentially be useful for both early diagnosis and monitoring the therapeutic response. The aim of this review is to update the most relevant molecular mechanisms underlying IRI, and also to discuss potential therapeutic targets in future clinical practice.

Highlights

  • According to recent estimates, in 2017 chronic kidney disease (CKD) had a global prevalence of 9.1% and caused the death of 1.2 million people

  • It has been demonstrated that the interstitial infiltration of neutrophils and macrophages is reduced in Toll-like receptors (TLRs)-4 knockout mice subjected to Ischemia reperfusion injury (IRI), lowering the inflammatory responses associated to the histopathological damage pattern, including tubular necrosis, tubular dilatation, the formation of casts and interstitial fibrosis

  • This study revealed the pivotal role of the NOD-like receptor signaling pathway and the relationship between its effectors and the infiltration of specific immune cell types during IRI

Read more

Summary

Introduction

In 2017 chronic kidney disease (CKD) had a global prevalence of 9.1% and caused the death of 1.2 million people. The incidence of DGF was much higher in grafts from DCD, with the risk of developing DGF being two-fold higher than donors after brain death (DBD) kidneys. 1-year graft function was marginally lower in recipients of DCD kidneys, at 5 years no difference between DCD and DBD kidneys was observed For both the cohorts, the rate of PNF was low, the incidence was slightly higher for DCD than DBD grafts (3.1% vs 2.5%, p = 0.04, in updated UK registries). IRI is a complex set of pathophysiologic mechanisms involving many biologic pathways, such as transcriptional reprogramming, the activation of apoptosis and cell death, the activation of the innate and adaptive immune responses, and endothelial dysfunction [18]. It is necessary to explore the single mechanisms involved in each phase

Ischemia
Reperfusion
Endothelial Dysfunction
Innate Immune Response
Innate to Adaptive Immune Response Translation
Adaptive Immune Response
Complement System
Cellular Metabolism Alterations in Ischemia-Reperfusion Injury
Potential Prevention and Therapeutic Strategies
Findings
Conclusions
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call